A new pilot study has found CBD to be effective at reducing symptoms in young people with treatment-resistant anxiety.
CBD may be effective in reducing the severity of symptoms and impairment caused by chronic anxiety, a pilot study led by Orygen, an Australian organisation offering support for young people’s mental health.
The Cannabidiol Youth Anxiety Pilot Study found that young people with treatment-resistant anxiety had an average 42.6 per cent reduction in their condition’s severity and impairment following 12 weeks of treatment with CBD.
The pilot study involved 31 participants aged 12–25 who were recruited from Orygen’s primary care services. The participants had a diagnosed anxiety disorder and had failed to show significant improvement in anxiety severity following at least five cognitive behavioural therapy (CBT) sessions.
The reduction in symptoms was observed on two different scales: a clinician-rated scale (Hamilton Anxiety Rating) which saw a 50.7 per cent reduction, and a self-rated scale (Overall Anxiety Severity and Impairment Scale) which saw a reduction of 42.6 per cent.
The study involved participants filling in a questionnaire on symptoms such as panic attacks, situational anxieties, worries and flashbacks.
The participants’ starting dose was one 200mg capsule of CBD per day, which was increased to 400mg after one week. Those who did not show significant improvement in anxiety symptoms had their dosage increased at 200mg increments up to 800mg per day.
All participants were offered biweekly CBT for 12 weeks.
Professor Paul Amminger, who led the study, said this level of improvement was “remarkable”.
“The young people had fewer panic attacks and could do things which they were previously unable to do like leave the house, go to school, participate in social situations, eat at restaurants, take public transport or attend appointments by themselves,” he said.
“That’s an amazing change in the group which has had treatment-resistant, long-standing severe to very severe anxiety.”
Australian Bureau of Statistics data released on 22 July showing anxiety was the most common form of mental ill-health in young people, affecting nearly a third (31.5 percent) of those aged 16–24 – almost double the rate of the general population.
Orygen started exploring cannabidiol as an anxiety treatment after it was found to be effective in reducing anxiety in adults.
Study co-investigator and Orygen Executive Director, Professor Patrick McGorry said the findings held promise for a significant number of young people.
He commented: “We’re seeing more and more young people experiencing anxiety – it’s the fasting growing form of mental ill-health in young people and we urgently need innovation in treatment. Cannabidiol is a promising treatment option which appears safe and effective. We need further research to confirm this and explore its value.”
Professor Amminger said: “The problem with current frontline treatments for anxiety – CBT and selective serotonin reuptake inhibitor (SSRI) antidepressant drugs – is that they only work in about half of the people who try them.
“Anxiety disorders are very common so that leaves a large number of young people untreated, struggling with symptoms and developing secondary conditions, for instance, depression and substance use disorders.
“It’s important to stress that cannabidiol does not induce any significant side effects or lead to the emergence of any neurological or psychiatric manifestations.
He continued: “Our pilot study found that CBD not only helped to reduce anxiety symptoms but it was also very well tolerated – the most common side-effects were mild sedation and mild fatigue but that was at the time when doses were increased and usually went away after a couple of days.
“We did not see side-effects like suicidal thoughts, irritability or sleep problems, which are not uncommon in people taking SSRIs.”
But although the findings are promising, further research is required.
Professor Amminger added: “An open-label pilot study is limited by its design. To see a treatment effect in the treatment-resistant group is encouraging, but it could still be a placebo effect.
“The next step is a randomised controlled trial, which is the gold standard to test a new intervention. Such a trial needs to be done in a much larger group – around 200 to 250 young people – to enable us to say with some certainty that there is, or is not, real treatment benefits and effects.”
The trial received financial and specialist technical support from the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.
- Medical Cannabis Division of Rokshaw Ltd Rebranding to Curaleaf Laboratories
- Breaking Ground: Morama Holdings Pioneers High-Quality, Organic Cannabis in Lesotho
- Patients to call for equity in medical cannabis access at UN Commission on Narcotic Drugs
- Medical cannabis has ‘negligible’ impact on driving performance – study
- Research shows ‘remarkable’ effects of cannabis in treatment of skin cancer
- Optimism despite delays: Ireland’s journey toward cannabis decriminalisation
News4 months ago
FSA drops recommended daily dose of CBD to 10mg – everything you need to know
Pain5 months ago
Medical cannabis ‘effective’ and ‘fast-acting’ for neuropathic pain – study
News4 months ago
UK government accepts ACMD recommendations for CBD products
Industry4 months ago
First UK-grown cannabis medicine expected by end of 2023
News5 months ago
The Netherlands to launch cannabis legalisation pilot December 2023
News5 months ago
BBC documentary highlights ‘pot luck’ of access to cannabis on NHS
Science5 months ago
New cannabis research: cancer, Type 2 diabetes, autism, fibromyalgia and skin disorders
News4 months ago
Europe’s first legal cannabis dispensaries to open under sixth Swiss pilot